Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
University of California, Davis Dr. John Laird Disease Team Therapy Development – Research Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia $3,728,384
University of California, Davis Dr. Vicki Wheelock Disease Team Therapy Development – Research MSC engineered to produce BDNF for the treatment of Huntington’s disease $8,924,235
StemCells, Inc. Dr. Nobuko Uchida Disease Team Therapy Development – Research Neural stem cell transplantation for chronic cervical spinal cord injury $0
University of California, Davis Nancy E. Lane Disease Team Therapy Development – Research Treatment of non-traumatic osteonecrosis with endogenous Mesenchymal stem cells $18,227,898
Salk Institute for Biological Studies Dr. David R Schubert Early Translational III Stem cell based small molecule therapy for Alzheimer’s disease $1,673,757
City of Hope, Beckman Research Institute Dr. Stephen J Forman Early Translational III Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells $5,215,447
Gladstone Institutes, J. David Dr. Deepak Srivastava Early Translational III Direct Cardiac Reprogramming for Heart Regeneration $5,795,871
University of California, San Diego Dr. Lawrence S. B. Goldstein Early Translational III Identifying Drugs for Alzheimer’s Disease with Human Neurons Made From Human IPS cells $1,774,420
University of California, San Diego Dr Yang Xu Early Translational III Human ES cell based therapy of heart failure without allogenic immune rejection $1,857,600
Stanford University Dr. Joseph C. Wu Early Translational III Heart Repair with Human Tissue Engineered Myocardium $4,395,080
University of California, San Francisco Dr Morton Cowan Early Translational III Gene Correction of Autologous Hematopoietic Stem Cells in Artemis Deficient SCID $3,862,367
Stanford University Professor Helen M. Blau PhD Early Translational III Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients $1,825,283
University of Southern California Dr. Toshio Miki Early Translational III Generation of hepatic cell from placental stem cell for congenital metabolic disorders $1,750,375
Children’s Hospital of Orange County Philip Schwartz Ph.D. Early Translational III Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease $4,266,015
University of California, San Francisco Dr. Holger F Willenbring Early Translational III Generation of safe and therapeutically effective human induced hepatocyte-like cells $1,544,170
Salk Institute for Biological Studies Juan Carlos Izpisua Belmonte Early Translational III Direct reprogramming towards vascular progenitors for the treatment of ischemia $2,340,000
University of California, San Diego Dr. Eric D. Adler Early Translational III Identification of Novel Therapeutics for Danon Disease Using an iPS Model of the Disease $1,701,575
University of California, Davis Walter Douglas Boyd Early Translational III Extracellular Matrix Bioscaffold Augmented with Human Stem Cells for Cardiovascular Repair $4,631,754
Stanford University Dr. Bertha Chen Early Translational III Autologous iPSC Therapy for Urinary Incontinence $4,715,738
University of California, San Diego Mark H Tuszynski Early Translational III Functional Neural Relay Formation by Human Neural Stem Cell Grafting in Spinal Cord Injury $4,600,447
University of California, Davis Prof. Kyriacos A. Athanasiou Ph.D Early Translational III Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells $1,735,703
University of California, Irvine Craig Michael Walsh Early Translational III Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells $4,535,005
Scripps Research Institute Peter G. Schultz Early Translational III Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis $2,559,333
University of California, San Francisco Dr. Arnold Kriegstein MD, PhD Early Translational III Human ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury $1,623,251
University of California, San Diego Dr. Gene Wei-Ming Yeo Early Translational III Molecules to Correct Aberrant RNA Signature in Human Diseased Neurons $1,532,323
University of California, Santa Cruz Dr. David Haussler Training Grant I-3 Training Program in Systems Biology of Stem Cells $1,133,701
University of California, Santa Barbara Dr. Dennis O. Clegg Training Grant I-3 UCSB Stem Cell Biology Training Program $975,334
Salk Institute for Biological Studies Juan Carlos Izpisua Belmonte Training Grant I-3 Training in the Biology of Human Enbryonic Stem Cells and Emerging Technologies $1,261,333
California Institute of Technology Paul H. Patterson Training Grant I-2 Training in Stem Cell Biology at CIT $1,817,214
Children’s Hospital of Los Angeles Dr. Donald B. Kohn Training Grant I-2 Training Grant 1 $2,173,872
Sanford Burnham Prebys Medical Discovery Institute Mark Mercola Training Grant I-2 Burnham Institute CIRM Stem Cell Training Grant (Type II) $1,061,865
Gladstone Institutes, J. David Dr. Robert W Mahley Training Grant I-2 Gladstone CIRM Scholar Program $2,192,073
Scripps Research Institute Peter G. Schultz Training Grant I-2 Training Grant I $1,021,395
University of California, Davis Dr. Frederick J Meyers MD Training Grant I-1 Stem Cell Research Training Grant $1,780,859
Stanford University Dr. Katja Weinacht Preclinical Stage Projects Therapeutic Restoration of Immune Function through iPSC-derived Human Thymic Epithelial Cells $12,999,871
EVADE Therapeutics Sonja Schrepfer Preclinical Stage Projects Hypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes $12,480,000
University of Southern California Charles Murry Preclinical Stage Projects Regenerating the Acutely Infarcted Heart with iPSC-Ventricular Cardiomyocytes. $7,499,998
University of California, Los Angeles Dr. Lili Yang Preclinical Stage Projects Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis $7,499,996
Scribe Therapeutics Brett Staahl Preclinical Stage Projects A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events $12,714,480
4D Molecular Therapeutics, Inc. Sara Collins Preclinical Stage Projects Gene Therapy for Alpha-1 Anti-Trypsin Deficiency $5,915,073
AcuraStem Incorporated Mr. Samuel V. Alworth MS, MBA Preclinical Stage Projects Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies $7,500,000
Cure Rare Disease Dr. Tahseen Mozaffar Preclinical Stage Projects Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 $7,292,297
Scribe Therapeutics Brett Staahl Preclinical Stage Projects A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia $13,000,000
Savanna Biotherapeutics, Inc. Dr. Sunil Gandhi Ph.D Preclinical Stage Projects Microglia replacement therapy for CSF1R-related Leukoencephalopathy $12,993,456
Cedars-Sinai Medical Center Dr. David Joseph Lefer Preclinical Stage Projects TY1 and Semaglutide to Treat Cardiometabolic HFpEF $10,571,220
University of California, San Diego Dr. Stephanie Cherqui Preclinical Stage Projects CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia $7,423,504
Cedars-Sinai Medical Center Dr. Alessandra Ciullo Preclinical Stage Projects Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy $10,419,929
Navega Therapeutics Ana Maria Moreno Preclinical Stage Projects Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders $9,486,864
Scripps Health Dr. Darryl D. D’Lima Preclinical Stage Projects Stem Cell-Based Cartilage Tissue Regeneration $12,715,000
Stanford University Dr. Bertha Chen Preclinical Stage Projects Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence $7,275,596
1 … 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

How to Apply

Learn More

Explore CIRM-Funded Clinical Trials

Learn More

Managing Your Grant

Learn More

See our Active Awards Portfolio

Learn More